23408-05-1

Basic information

• Product Name: Benzoic acid, 2-hydroxy-, 1,1-dimethylethyl ester
• CAS NO: 23408-05-1
• Molecular Formula: C11H14O3
• Molecular Weight: 194.23
• Mol File: 23408-05-1.mol
• Article Data: 17

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 2-hydroxy-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 2-hydroxy-, 1,1-dimethylethyl ester(23408-05-1)
• EPA Substance Registry System: Benzoic acid, 2-hydroxy-, 1,1-dimethylethyl ester(23408-05-1)

Safety Data

• Hazardous Substances Data: 23408-05-1(Hazardous Substances Data)

Upstream product

• 774-65-2 benzoic acid tert-butyl ester 
• 530-62-1 1,1'-carbonyldiimidazole 
• 69-72-7 salicylic acid 
• 75-65-0 tert-butyl alcohol 
• 36805-97-7 N,N-dimethylformamide di-tert-butyl acetal 
• 115-11-7 isobutene 

Downstream Products

• 616896-98-1 tert-butyl 2-(2-tert-butoxy-2-oxoethoxy)benzoate 
• 911432-61-6 N-Boc-L-[2-(tert-butoxycarbonyl)phenyl]-1,3-thiazolidine-4-carboxylate 
• 935472-63-2 L-2-[(1,3-thiazolidin-4-ylcarbonyl)oxy]benzoic acid 
• 258330-69-7 tris(salicyl) trimesate 
• 64407-57-4 N,N-dicyclohexylurea 
• 1221891-34-4 C₂₃H₂₁NO₃ 
• 1316749-15-1 tert-butyl 2-((2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-yloxy)butanoyl)oxy)benzoate 

Relevant articles and documents

Six-membered ring formamide compounds, synthesis method and applications thereof

The invention discloses a class of six-membered ring formamide compounds represented by formulas (I)-(II), a medicinal derivative and a hydrate thereof, a composition containing the six-membered ringformamide compound, and a preparation method of the six-

ACYLATED ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AUTOIMMUNE DISORDERS

Disclosed herein are acylated active agents (e.g., acylated catechin polyphenols, acylated carotenoids, acylated mesalamines, acylated sugars, acylated shikimic acids, acylated ellagic acid, acylated ellagic acid analogue, and acylated hydroxybenzoic acids), active agent combinations (e.g., with a second agent that is a fatty acid) and methods of their use, e.g., for modulating an autoimmunity marker or for treating an autoimmune disorder.

Salicylic acid-based fumarate derivatives and its use in treatment on Parkinsonism and other neurodegenerative diseases

The invention provides salicylic acid-based fumarate derivatives as novel compounds. The salicylic acid-based fumarate derivatives have a general structural formula (A) shown in the description. In the general formula (A), R1 represents one of H, Na